Overview
Evio builds pharmacy solutions by partnering with health plans to improve how people get and use medications, focusing on patients, providers, and the health system. It uses real-world evidence to ensure patients receive the right drugs in a simple and affordable way, coordinating data, care teams, and benefit design across the medication journey. Unlike competitors, Evio ties real-world evidence to payer and provider workflows and targets the full medication pathway to drive affordability and appropriate prescribing. The goal is to make the medication experience safer, easier to navigate, and less expensive while reducing waste and friction in the healthcare system.
Work here?Claim your company
Simplify's take
What believers are saying
- March 2025 Wellmark investment expanded ownership to six plans and widened Midwest reach.
- November 2026 hiring for contracting and systems roles shows active product commercialization.
- Direct purchase biosimilar agreements can cut drug spend and strengthen Evio's health-plan retention.
What critics are saying
- Pfizer contract litigation, docket 1:23-cv-07371, keeps legal overhang alive in November 2026.
- No public 2026 revenue disclosures; job board signals dependence on future contracting growth.
- If manufacturer deals stall, Evio becomes a niche payer consortium with limited standalone value.
What makes Evio unique
- Six Blue health plans own Evio, giving direct payer distribution and data access.
- Evio Access bundles RWE analytics, contracting, and member engagement into one pharmacy platform.
- October 2024 adalimumab biosimilar deal shows manufacturer-contracting execution beyond standard PBM rebates.
Help us improve and share your feedback! Did you find this helpful?